Regional ventricular and atrial strain to distinguish cardiac involvement of Fabry disease and amyloidosis

Regional ventricular and atrial strain to distinguish cardiac involvement of Fabry disease and amyloidosis - Fabry_VS_Amyloidosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027403

Enrollment

200

Registered

2021-12-20

Start date

2021-11-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyloidosis Fabry disease

Interventions

Group 1: The following meassurements are planned: Symptoms Medication Laboratory meassurements: Creatinin, eGFR CKD-EPI, N-terminal pro brain natriuretic peptide (NTproBNP), Troponin ECG Transthoracic

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Fabry Disease, amyloidosis with an echocardiography performed before 31.10.21

Exclusion criteria

Exclusion criteria: Low image quality of echocardiographic data

Design outcomes

Primary

Measure	Time frame
atrial and ventricular strain	—

Secondary

Measure	Time frame
echocardiographic routine parameters (left ventricular function and hypertrophy)	—

Countries

Germany

Contacts

Public ContactAnna Brand

Charité Campus Charité Mitte

anna.brand@charite.de+49 30 450 513 142

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 9, 2026